Cytokinetics Announces European Medicines Agency Validation - GlobeNewswire
Cytokinetics announced EMA validation of aficamten's MAA for obstructive HCM, supported by SEQUOIA-HCM trial results. The drug, a cardiac myosin inhibitor, aims to improve exercise capacity and relieve HCM symptoms.
Highlighted Terms
obstructive hypertrophic cardiomyopathymetoprololCK-089CytokineticsCommittee for Medicinal Products for Human UseU.S. Food and Drug AdministrationNational Medical Products Administrationheart failure with preserved ejection fractionnon-obstructive hypertrophic cardiomyopathyaficamtenEuropean Medicines Agencyomecamtiv mecarbilhypertrophic cardiomyopathyheart failure with severely reduced ejection fractionCK-586
Related News
Cytokinetics Announces European Medicines Agency Validation - GlobeNewswire
Cytokinetics announced EMA validation of aficamten's MAA for obstructive HCM, supported by SEQUOIA-HCM trial results. The drug, a cardiac myosin inhibitor, aims to improve exercise capacity and relieve HCM symptoms.